
Implanet entered into exclusive negotiations regarding the sale of its MADISON™ total knee prosthesis. The transaction addresses all assets, rights, titles and contracts pertaining to design and marketing of Madison implants.
This is in line with Implanet’s strategy to focus on accelerating growth of its spine business segment.
Implanet will continue development of its range of JAZZ™ products to treat vertebral disorders requiring spinal fusion. Further, the company will accelerate sales across priority geographic regions such as the U.S., Brazil and Europe.
This project is subject to a certain number of conditions including the carrying out of
financial, technical, legal and regulatory audits, an agreement regarding the documentation and the granting of regulatory approval.
CEO Ludovic Lastennet said, “Implanet is delighted to announce the initiation of
exclusive negotiations to sell its Knee platform. The objective, to accelerate our growth, is to focus our strategy entirely on our Spine activities. In the future, Implanet will be 100% devoted to the treatment of spinal disorders. Thanks to this operation, we will benefit from significant additional financial resources to strengthen our organic growth and, at the same time, be able to seize potential opportunities for acquisitions that correspond with our goal of making Implanet a powerful player in the field of spinal pathologies.”
Implanet entered into exclusive negotiations regarding the sale of its MADISON™ total knee prosthesis. The transaction addresses all assets, rights, titles and contracts pertaining to design and marketing of Madison implants.
This is in line with Implanet’s strategy to focus on accelerating growth of its spine business segment.
Implanet will...
Implanet entered into exclusive negotiations regarding the sale of its MADISON™ total knee prosthesis. The transaction addresses all assets, rights, titles and contracts pertaining to design and marketing of Madison implants.
This is in line with Implanet’s strategy to focus on accelerating growth of its spine business segment.
Implanet will continue development of its range of JAZZ™ products to treat vertebral disorders requiring spinal fusion. Further, the company will accelerate sales across priority geographic regions such as the U.S., Brazil and Europe.
This project is subject to a certain number of conditions including the carrying out of
financial, technical, legal and regulatory audits, an agreement regarding the documentation and the granting of regulatory approval.
CEO Ludovic Lastennet said, “Implanet is delighted to announce the initiation of
exclusive negotiations to sell its Knee platform. The objective, to accelerate our growth, is to focus our strategy entirely on our Spine activities. In the future, Implanet will be 100% devoted to the treatment of spinal disorders. Thanks to this operation, we will benefit from significant additional financial resources to strengthen our organic growth and, at the same time, be able to seize potential opportunities for acquisitions that correspond with our goal of making Implanet a powerful player in the field of spinal pathologies.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.